半岛bd体育手机客户端 说明
包装
5, 25 mg in glass bottle
生化/生理作用
BMS-193885 is a potent, selective Y1 antagonist that is active in both acute and chronic animal models of food intake. Although it is active in vivo, it is not orally bioavailable due to poor intestinal absorption, so it is not being pursued for pharmaceutical development. BMS-193885 has been used as a pre-clinical proof of concept tool for showing efficacy of Y1 antagonism in treating obesity.
特点和优势
This compound was developed by Bristol-Myers Squibb. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
This compound is featured on the Neuropeptide Y Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
基本信息
| 经验(实验)分子式 | C33H42N4O6 |
| 分子量 | 590.71 |
| MDL编号 | MFCD16878998 |
| PubChem化学物质编号 | 329773248 |
| NACRES | NA.77 |
半岛bd体育手机客户端 性质
| 质量水平 | 100 |
| 测定 | ≥98% (HPLC) |
| 形式 | powder |
| 颜色 | light yellow to yellow |
| 溶解性 | DMSO: >10 mg/mL |
| 创始人 | Bristol-Myers Squibb |
| 储存温度 | ?20℃ |
| SMILES string | COC(=O)C1=C(C)NC(C)=C(C1c2cccc(NC(=O)NCCCN3CCC(CC3)c4cccc(OC)c4)c2)C(=O)OC |
| InChI | 1S/C33H42N4O6/c1-21-28(31(38)42-4)30(29(22(2)35-21)32(39)43-5)25-10-6-11-26(19-25)36-33(40)34-15-8-16-37-17-13-23(14-18-37)24-9-7-12-27(20-24)41-3/h6-7,9-12,19-20,23,30,35H,8,13-18H2,1-5H3,(H2,34,36,40) |
| InChI key | WMYSXJSJXZFODY-UHFFFAOYSA-N |
安全信息
| 象形图 |  |
| 警示用语： | Warning |
| 危险声明 | H302 |
| 危险分类 | Acute Tox. 4 Oral |
| 储存分类代码 | 11 - Combustible Solids |
| WGK | WGK 3 |
| 闪点(F) | Not applicable |
| 闪点(C) | Not applicable |
m.cnreagent.com
